Intellipharmaceutics International Inc - ESG Rating & Company Profile powered by AI
Detailed ESG analysis of Intellipharmaceutics International Inc are accessed by logging in. If you work at Intellipharmaceutics International Inc and you would like to use your ESG rating, please get in touch. This analysis of Intellipharmaceutics International Inc incorporates information from across the internet as well as from available disclosures by Intellipharmaceutics International Inc.
Intellipharmaceutics International Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.2; made up of an environmental score of 4.0, social score of 0.0 and governance score of 2.7.
2.2
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1529 | Slang Worldwide Inc | 2.3 | Medium |
| 1529 | Vanda Pharmaceuticals Inc | 2.3 | Medium |
| 1551 | Intellipharmaceutics International Inc | 2.2 | Medium |
| 1551 | Brawn Biotech Ltd | 2.2 | Medium |
| 1551 | Pangaea Oncology SA | 2.2 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Intellipharmaceutics International Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Intellipharmaceutics International Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Intellipharmaceutics International Inc report the average age of the workforce?
Sign up for free to unlockDoes Intellipharmaceutics International Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Intellipharmaceutics International Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Intellipharmaceutics International Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Intellipharmaceutics International Inc offer flexible work?
Sign up for free to unlockDoes Intellipharmaceutics International Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Intellipharmaceutics International Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Intellipharmaceutics International Inc conduct supply chain audits?
Sign up for free to unlockDoes Intellipharmaceutics International Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Intellipharmaceutics International Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Intellipharmaceutics International Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Intellipharmaceutics International Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Intellipharmaceutics International Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Intellipharmaceutics International Inc disclose water use targets?
Sign up for free to unlockDoes Intellipharmaceutics International Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Intellipharmaceutics International Inc have a product recall in the last two years?
Sign up for free to unlockDoes Intellipharmaceutics International Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Intellipharmaceutics International Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Intellipharmaceutics International Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Intellipharmaceutics International Inc disclose parental leave metrics?
Sign up for free to unlockDoes Intellipharmaceutics International Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Intellipharmaceutics International Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Intellipharmaceutics International Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Intellipharmaceutics International Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Intellipharmaceutics International Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Intellipharmaceutics International Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Intellipharmaceutics International Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Intellipharmaceutics International Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Intellipharmaceutics International Inc disclose its waste policy?
Sign up for free to unlockDoes Intellipharmaceutics International Inc report according to TCFD requirements?
Sign up for free to unlockDoes Intellipharmaceutics International Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Intellipharmaceutics International Inc disclose energy use targets?
Sign up for free to unlockDoes Intellipharmaceutics International Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Intellipharmaceutics International Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Intellipharmaceutics International Inc
These potential risks are based on the size, segment and geographies of the company.
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.